Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1983 2
1984 1
1990 1
1992 2
1994 1
1995 7
1996 7
1997 6
1998 3
1999 3
2000 3
2001 4
2002 8
2004 3
2005 1
2006 2
2007 3
2008 1
2010 2
2011 2
2012 1
2015 1
2016 2
2017 2
2018 4
2019 4
2020 9
2021 7
2022 6
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.
Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Danese S, et al. Among authors: banfield c. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2324-2332.e6. doi: 10.1016/j.cgh.2021.06.011. Epub 2021 Jun 12. Clin Gastroenterol Hepatol. 2021. PMID: 34126262 Clinical Trial.
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA, Dowty ME, Page K, Vincent MS, Zhang W, Zhu L, Peeva E. Guttman-Yassky E, et al. Among authors: banfield c. J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1. J Allergy Clin Immunol. 2022. PMID: 34863853 Free article. Clinical Trial.
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. Among authors: banfield c. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE. Sandborn WJ, et al. Among authors: banfield c. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2616-2628.e7. doi: 10.1016/j.cgh.2022.12.029. Epub 2023 Jan 6. Clin Gastroenterol Hepatol. 2023. PMID: 36623678 Free article. Clinical Trial.
First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G, Hassan-Zahraee M, Brown LS, Hung KE, Pawlak S, Lepsy C. Banfield C, et al. Br J Clin Pharmacol. 2020 Apr;86(4):812-824. doi: 10.1111/bcp.14187. Epub 2020 Jan 28. Br J Clin Pharmacol. 2020. PMID: 31758576 Free PMC article. Clinical Trial.
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Gooderham MJ, et al. Among authors: banfield c. JAMA Dermatol. 2019 Dec 1;155(12):1371-1379. doi: 10.1001/jamadermatol.2019.2855. JAMA Dermatol. 2019. PMID: 31577341 Free PMC article. Clinical Trial.
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, Mangold AR, Ghosh P, Banfield C, Oemar B. Kimball AB, et al. Among authors: banfield c. NEJM Evid. 2024 Mar;3(3):EVIDoa2300155. doi: 10.1056/EVIDoa2300155. Epub 2024 Feb 9. NEJM Evid. 2024. PMID: 38335032 Clinical Trial.
Acrokeratosis paraneoplastica in tonsillar carcinoma.
Alband N, Danila I, Oliver C, Bardsley V, Banfield C, Van-De-Velde V. Alband N, et al. Among authors: banfield c. Eur J Dermatol. 2023 Feb 1;33(1):62-64. doi: 10.1684/ejd.2023.4437. Eur J Dermatol. 2023. PMID: 37178042 No abstract available.
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Landis MN, Arya M, Smith S, Draelos Z, Usdan L, Tarabar S, Pradhan V, Aggarwal S, Banfield C, Peeva E, Vincent MS, Sikirica V, Xenakis J, Beebe JS. Landis MN, et al. Among authors: banfield c. Br J Dermatol. 2022 Dec;187(6):878-887. doi: 10.1111/bjd.21826. Epub 2022 Oct 23. Br J Dermatol. 2022. PMID: 35986699 Free PMC article. Clinical Trial.
108 results